Browse >
Home / Archive: January 2009
Does shift work predispose you to cancer by altering the body's response to hormones? And if so, can a dietary supplement help? Those are the questions researchers at The Cancer Institute of New Jersey (CINJ) hope to answer through a new study, which recently received $600,000 in funding from The V Foundation for Cancer Research. CINJ is a Center of Excellence of UMDNJ-Robert Wood Johnson Medical School.
Screening a chemical library of 200,000 compounds, researchers at UT Southwestern Medical Center have identified two new classes that can be used to study and possibly manipulate a cellular pathway involved in many types of cancer and degenerative diseases. "The identification of these chemicals and their targets within this cellular pathway represents an important step in developing therapeutic agents," said Dr.
Biology exists in a physical world. That's a fact cancer researchers are beginning to recognize as they look to include concepts of physics and mathematics in their efforts to understand how cancer develops -- and how to stop it. The movement, led by researchers at the University of Michigan Comprehensive Cancer Center, has come to a head with a new section in one of the top cancer research journals and a new grant program from the National Cancer Institute.
A team of researchers at the University of California, San Diego (UCSD) and the Moores UCSD Cancer Center have developed a rapid, automated image screening process to distinguish breast cancer cells from normal cells. The technique, which is based on the density of cells seen on a microscope slide, may eventually lead to better ways for surgeons to determine if they have removed all of the cancer during breast-conserving cancer surgery and cut down on the number of needed second operations.
Scientists have uncovered an interesting connection between two important protein kinase signaling pathways that are associated with cancer. The research, published by Cell Press in the January 30th issue of the journal Molecular Cell, may direct new therapeutic strategies for multiple types of cancer. The protein kinase LKB1 is a known tumor suppressor and the LKB1-AMPK signaling pathway couples energy metabolism with cell growth, proliferation and survival.
Last week, a presidential limousine shuttled Barack Obama to the most important job in his life. Scientists at the Stanford University School of Medicine have now identified a protein that does much the same for the telomerase enzyme - ferrying the critically important clump of proteins around to repair the ends of chromosomes that are lost during normal replication. Without such ongoing maintenance, stem cells would soon cease dividing and embryos would fail to develop.
Medical News Today is pleased to announce the launch of a new Lymphology / Lymphedema channel. The section will include news on lymphology, lymphatic filariasis (elephantiasis), lymphedema (lymphoedema).
TGen Clinical Research Services (TCRS) at Scottsdale Healthcare and Mayo Clinic are testing a new drug that may offer broad potential to treat solid tumors. Clinical trials of the drug TH-302 are being conducted at TGen Clinical Research Services at Scottsdale Healthcare, a partnership of the Phoenix-based Translational Genomics Research Institute (TGen) and Scottsdale-based Scottsdale Healthcare Corp., and at Mayo Clinic in Arizona. Dr.
NEW YORK -- Pfizer Inc announced today the discontinuation of a Phase III study of its investigational agent axitinib for the treatment of advanced pancreatic cancer. Based on an interim analysis, an independent Data Safety Monitoring Board (DSMB) found no evidence of improvement in the primary endpoint of survival in patients treated with axitinib and gemcitabine, compared to gemcitabine alone, the current standard of care for patients with advanced pancreatic cancer. "These results were disappointing, given the trend towards prolonged survival seen in a Phase II study of axitinib in this extremely difficult-to-treat patient population," said Mace L. Rothenberg, M.D., senior vice president, clinical development and med...
National Cancer Prevention Month kicks off February 1, and the American Society of Clinical Oncology (ASCO) is highlighting the oncologist's role in cancer prevention and in assessing a person's risk of getting cancer in a new policy statement published in the Journal of Clinical Oncology (JCO) this month. "Oncologists are increasingly being asked about cancer risk assessment and prevention strategies by our patients," said Richard L.
Next Page »
